TabletsClinical Overview
Rabeprazole Gastro-Resistant Tablets (20mg) is a second-generation proton pump inhibitor on the WHO Model List of Essential Medicines. It binds to gastric H+/K+-ATPase with high potency and dissociates more rapidly than first-generation PPIs, producing faster acid inhibition within hours of the first dose. Indicated for acute duodenal and gastric ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the morning before breakfast. Swallow whole with water; do not crush, split, or chew the enteric-coated tablet. Duration: 4 weeks for duodenal ulcer, 4-8 weeks for GERD and gastric ulcer.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Headache, diarrhea, nausea, abdominal discomfort, flatulence, rhinitis, insomnia. Rare/Severe: Hypomagnesemia, interstitial nephritis, bone fractures with long-term therapy, and severe cutaneous adverse reactions.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Primarily metabolized non-enzymatically via reduction to thioether, exhibiting minimal CYP2C19-mediated drug-drug interactions compared to omeprazole. Safe for use with clopidogrel.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.
Rabeprazole 20mg (Enteric Coated) + Domperidone 30mg (Sustained Release) Capsules
Rabeprazole Sodium (20mg enteric-coated) and Domperidone (10mg/30mg sustained-release) is a rapid-onset PPI and prokinetic combination. Rabeprazole has a higher pKa (~5.0) than other PPIs, allowing faster activation at higher pH and achieving rapid, potent inhibition of gastric H+/K+-ATPase pumps from the first dose. Domperidone provides dopamine D2 antagonism to enhance lower esophageal sphincter tone and accelerate gastric emptying. Indicated for erosive esophagitis, GERD, hypersecretory conditions, and dyspeptic symptom complexes (nausea, postprandial fullness, acid regurgitation).
Rabeprazole 20mg + Domperidone 10mg Capsules
Rabeprazole Sodium (20mg enteric-coated) and Domperidone (10mg/30mg sustained-release) is a rapid-onset PPI and prokinetic combination. Rabeprazole has a higher pKa (~5.0) than other PPIs, allowing faster activation at higher pH and achieving rapid, potent inhibition of gastric H+/K+-ATPase pumps from the first dose. Domperidone provides dopamine D2 antagonism to enhance lower esophageal sphincter tone and accelerate gastric emptying. Indicated for erosive esophagitis, GERD, hypersecretory conditions, and dyspeptic symptom complexes (nausea, postprandial fullness, acid regurgitation).
Rabeprazole Sodium (Gastro-resistant) 20mg + Itopride Hydrochloride Prolonged release 150mg Capsules
Rabeprazole Sodium (20mg gastro-resistant) and Itopride Hydrochloride (150mg prolonged-release) combines an antisecretory PPI with an AChE-inhibiting and D2-antagonizing prokinetic. Itopride boosts acetylcholine availability to coordinate gastroduodenal contractions without prolonging cardiac QT intervals or elevating prolactin substantially. Indicated for GERD, reflux esophagitis, non-erosive reflux disease (NERD), and dysmotility-like functional dyspepsia.
Aceclofenac 200mg (Sustained release) + Rabeprazole Sodium 20mg (Enteric-coated) Capsules
Aceclofenac (200mg sustained-release) and Rabeprazole Sodium (20mg enteric-coated) Capsules is a gastro-protective NSAID combination. Aceclofenac is a phenylacetic acid NSAID that selectively inhibits COX-2 over COX-1, relieving joint pain and inflammation in osteoarthritis and ankylosing spondylitis. Rabeprazole is a fast-acting proton pump inhibitor that suppresses gastric acid secretion by blocking parietal cell H+/K+-ATPase, neutralizing the risk of NSAID-induced gastric ulceration, erosions, and GI bleeding. Indicated for chronic arthritis pain, osteoarthritis, and ankylosing spondylitis in patients with high gastrointestinal risk.